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Available online xxxxBackground: Severe mental illness (SMI) is associated with excess cardiovascular disease (CVD) morbidity, but
little is known on provision of preventative interventions. We investigated statin initiation for primary CVD pre-
vention in individuals with and without SMI.
Methods:We used primary care data from The Health Improvement Network from 2006 to 2015 for UK patients
aged 30–99 years with no pre-existing CVD conditions and selected individuals with schizophrenia (n=13,252)
or bipolar disorder (n= 11,994). In addition, we identiﬁed samples of individuals without schizophrenia (n=
66,060) and bipolar disorder (n = 59,765), but with similar age and gender distribution. Missing data on CVD
covariates were estimated using multiple imputation. Statin prescribing differences between individuals with
and without SMI were investigated using multivariable Poisson regression models.
Results: Initiation of statin prescribingwas between 2 and 3 fold higher in people aged 30–59 yearswith SMI than
in those without after adjusting for CVD covariates. The rates in those aged 60–74 years with SMIwere similar or
slightly higher relative to those without SMI. The incidence rate ratio (IRR) was 1.15 (95% CI 1.03–1.28) for bipo-
lar disorder and 1.00 (0.91–1.11) for schizophrenia. The rate of statin prescribing was lower (IRR 0.81 (0.66–
0.98)) amongst the oldest (aged 75+ years) with schizophrenia relative to those without schizophrenia.
Conclusions: Despite higher rates of new statin prescriptions to younger individuals with SMI relative to individ-
uals without SMI, there was evidence of lower rates of statin initiation for older individuals with schizophrenia,
and this group may beneﬁt from additional measures to prevent CVD.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Schizophrenia
Bipolar disorder
Cardiovascular disease
Health inequalities
Statins1. Introduction
Severemental illness (SMI) including schizophrenia and bipolar dis-
order is associated with a high burden of physical comorbidity: rates of
cardiovascular disease (CVD) are two to threefold higher in younger
people with an SMI diagnosis than comparable individuals without
SMI (Osborn et al., 2007; Laursen et al., 2011). CVD-associatedmortality
is three times higher amongst people with SMI than the general popu-
lation and makes a sizable contribution to the 15–20 year deﬁcit in life
expectancy experienced by this group (Ringen et al., 2014). In the
past, both the provision and quality of treatment for existing CVD condi-
tions has been lower for individuals with SMI than the general popula-
tion (Mitchell et al., 2012; Mitchell and Lord, 2010; Hippisley-Cox et al.,lth Informatics Research, 222
. This is an open access article under
l., Statin prescribing for prev
phr. Res. (2017), http://dx.do2007): however little is known about the prescribing of statins for pri-
mary prevention of CVD.
Guidelines from the National Institute of Healthcare and Clinical Ex-
cellence (NICE) identify people with SMI as a speciﬁc population for
whom statin prescribing for primary prevention should be considered
at the same threshold (currently N10% 10 year CVD risk) as the general
population (National Institute for Health and Clinical Excellence, 2014b;
National Institute for Health and Clinical Excellence, 2014c; National
Institute for Health and Clinical Excellence, 2014a). Statins are cost-ef-
fective for preventing CVD events within randomised controlled trial
(RCT) populations without mental illness (Taylor et al., 2013) and
there is growing evidence to suggest that statins are similarly effective
in people with SMI (Ojala et al., 2008; De Hert et al., 2006; Hanssens
et al., 2007; Vincenzi et al., 2014, Blackburn et al., 2017). Given such ev-
idence of effectiveness there is a need to evaluate statin prescribing in
practice and to establish where policy intervention is needed to im-
prove health outcomes for people with SMI.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ention of cardiovascular disease amongst people with severe mental
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CVD should usually precede statin prescribing for primary CVD preven-
tion in both people with andwithout SMI. Over the past decade, nation-
al guidance and ﬁnancial incentives for physical health screening have
been introduced for individuals with SMI (National Institute for Health
and Clinical Excellance, 2006; National Institute for Health Clinical
Excellence, 2009) (Fig. 1). The speciﬁcation of these health checks has
changed over time, with corresponding increases in CVD screening re-
ported for the period 2000–2007 (Osborn et al., 2011) but little evalua-
tion thereafter. Similar strategies – such as the NHS Health Check (also
outlined in Fig. 1) – applied to the general population have tended to re-
sult in low levels of uptake (Artac et al., 2013; Dalton and Soljak, 2012)
that is inversely correlated with need (Bender et al., 2014; Krogsboll et
al., 2012a; Krogsboll et al., 2012b; Waller et al., 1990), thus generating
concern that such policies may widen health inequalities (Capewell
and Graham, 2010).
To date, there is limited evidence on CVD prevention in people with
SMI and a paucity of research with a focus on statin prescribing for pri-
mary CVD prevention (Cooper et al., 2016; Tosh et al., 2010). This study
therefore aims to evaluate patterns in new statin prescriptions to indi-
viduals with SMI, compared to people without SMI, for the period
from the 1st January 2006 to 31st December 2015.
2. Experimental/materials and methods
A retrospective cohort study was developed using data extracted
from The Health Improvement Network (THIN) primary care database
(IMS Health, 2015). THIN captures anonymised data from electronic
health records frompatients registered at 587 general practice (GP) sur-
geries across the United Kingdom (UK); reﬂecting 5.7% of the total pop-
ulation (IMS Health, 2015). The majority of individuals with SMI
routinely access primary care (Reilly et al., 2012) and the validity of
these diagnoses in computer records has been established (Hardoon
et al., 2013; Nazareth et al., 1993). THIN data are recorded as hierarchi-
cal medical codes (Read codes), free text comments, drug codes for pre-
scribed medications, referrals and additional health information such as
laboratory test results and biometrics (Chisholm, 1990; Stuart-Buttle et
al., 1996). Townsend score for the quintile of deprivation is recorded in
THIN and is assigned on the basis of deprivation at the level of the corre-
sponding enumeration district (areas of approximately 150 households)
for a patient's address (Townsend et al., 1986). All data management
and analysis were undertaken with Stata v14 (StataCorp., 2015).
2.1. Study population
Data for all GP surgeries were extracted for eligible individuals for
the period 1st January 2006 to 31st December 2015. Individuals with a
diagnosis of schizophrenia or bipolar disorder were categorised asFig. 1. Cardiovascular screening and prescribing policy developm
Please cite this article as: Blackburn, R., et al., Statin prescribing for prev
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strata, up to 5 times as many people from the same practice who were
similar in terms of age at baseline (±5 years) and gender but without
an SMI diagnosis were selected for inclusion in a parallel cohort.
Entry into the study was at the latest of; i) 30th birthday, ii) date of
GP registration plus 6months and iii) 1st January 2006. In addition, data
were censored for time points prior to the GP surgery meeting accept-
able levels of data quality, which were assessed in terms of mortality
rate and computer usage (Horsfall et al., 2012; Maguire et al., 2009).
Exit from the study occurred at the earliest of i) 100th birthday ii) out
of practice transfer iii) death iv) ﬁrst statin prescription, v) CVD event
or vi) 31st December 2015. Individuals were excluded from the study
if they had a diagnosis of CVD prior to enrolment in the study or had a
record of a statin prescription prior to the study start date. Thus, individ-
uals were not eligible to enter the study until six months after the date
of registration: this was in order to exclude people with prevalent diag-
noses of cardiovascular disease or who were continuing statin treat-
ment (Lewis et al., 2005). Patient data were extracted on SMI
diagnoses, patient age, gender, Townsend score and physical health
data (blood pressure, height, weight, total cholesterol, high density lipo-
protein cholesterol (HDL-C), diabetes, smoking status and antihyper-
tensive prescribing) and statin prescriptions. Body mass index (BMI)
was estimated from weight and adult height. Measurements of blood
pressure, height,weight, total cholesterol, HDL-C and smoking status re-
corded within the same calendar year were combined (as a mean or
mode). Data on time-varying characteristics (e.g. blood pressure)
were summarised for three 1 year calendar time points (2007, 2011
and 2015) and differences examined by unpaired t-test (or Mann–
Whitney U test if not normally distributed) for continuous data and
Chi-squared test for categorical data.
Somedataweremissing for smoking, height, weight, blood pressure,
total cholesterol andHDL\\C.Missing valueswere estimated usingmul-
tiple imputation with the twofold Fully Conditional Speciﬁcation meth-
od, which makes use of the full longitudinal health record (Nevalainen
et al., 2009; Welch et al., 2014; Osborn et al., 2015). The imputation
model included variables for all patient data outlined above including
the outcome (statin prescribing) and associated Nelson Aalen cumula-
tive hazard function.We created 10 imputed datasets fromwhich com-
bined effect estimates and associated standard errors were derived
using appropriate statisticalmethods (Welch et al., 2014). Greater num-
bers of imputations were not feasible given the large size of the dataset.
Height, weight, blood pressure, total cholesterol and HDL-C were in-
cluded in the imputation model in log form.
2.2. Analysis of statin prescribing
Analyses were stratiﬁed into four pre-speciﬁed age groups (30–39,
40–59, 60–74, 75–99 years), which are compatible with screeningents in individuals with SMI and the UK general population.
ention of cardiovascular disease amongst people with severe mental
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dividuals with SMI (National Institute for Health Clinical Excellence,
2009; National Institute for Health and Clinical Excellance, 2006). Annu-
al rates of new statin prescriptions were calculated for each year by di-
viding the number of individuals in the 12 month period with a ﬁrst
statin prescription by the total person-time at risk.
Evidence of differences in statin prescribing between people with
and without SMI diagnoses (the exposure of interest) were assessed
using multivariable Poisson regression models with new statin pre-
scriptions as the outcome. Models accounted for follow-up time and
were adjusted for patient characteristics during the calendar year in
which an individual started follow-up. Model 1 included data that
were complete (ﬁve year age band, gender and Townsend quintile of
deprivation).We also examined the impact of characteristics associated
with CVD risk on statin prescribing (Model 2); diabetes status, antihy-
pertensive prescribing, smoking status, BMI, total cholesterol and
HDL-C in addition to age, gender and Townsend score. Model ﬁtting
within the subset of individuals with complete data was used to guide
inclusion of continuous variables in linear or log-linear form.
As a sensitivity analysis we applied a different modelling strategy
(Model 3) which adjusted for strata of estimated 10 year CVD risk
(b5%, 5–10%, 11–20%, 21–40%, N50%) in addition to the variables in
Model 1. The sensitivity analysis was included to assess whether differ-
ent approaches for adjusting for cardiovascular risk as a confounding
factor changed the interpretation of our results from themain analyses.
CVD risk was estimated using the ofﬁce version of the Framingham risk
score (D'Agostino et al., 2008): age, gender, diabetes status, antihyper-
tensive prescribing, BMI, systolic blood pressure and smoking status.
3. Results
A total of 25,246 individuals with an SMI diagnosis were identiﬁed.
Of these 13,252 (52%) had a diagnosis of schizophrenia and 11,994
(48%) a diagnosis of bipolar disorder. We identiﬁed 66,060 individuals
without a diagnosis of SMI but with a similar age and gender distribu-
tion as the individuals with schizophrenia. Likewise, we identiﬁed
59,765 individualswithout SMI butwith a similar age and gender distri-
bution as the individuals with bipolar disorder. The characteristics of in-
dividuals included in the SMI and non-SMI cohorts are outlined in Table
1. The number of individuals entering and exiting the cohort at each
time point is outlined in the supplementary material (Supplementary
Table 1). The median age at the start of follow up was 48 years for
schizophrenia and 45 years for bipolar disorder. Diagnoses of schizo-
phrenia were more common amongst men (60%males), whereas bipo-
lar disorder was more frequently diagnosed amongst women (61%
females).
Time-varying characteristics recorded for the study population (at
three separate time points) are summarised in Table 2a, Table 2b andTable 1
Characteristics of the study population during the period January 2006 to December 2015.
Characteristic n= 13,252
Schizophrenia (%)
Age at study entry 30–39 years 4134 31%
40–59 years 5717 43%
60–74 years 2305 17%
75–99 years 1096 8%
Median age at start in years [IQR] 47.5 [37.5–60.5]
Sex Males 7901 60%
Townsend score
1 Least deprived 1472 11%
2 1856 14%
3 2682 20%
4 3451 26%
5 Most deprived 3791 29%
SMI; severe mental illness, CVD; cardiovascular disease, QOF; Quality and Outcomes Framewo
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vary across the time points and that measured characteristics generally
suggest a higher cardiovascular risk proﬁle amongst people with SMI in
terms of higher smoking and diabetes prevalence, and lower HDL-C
concentration. By contrast, systolic blood pressure was generally
lower amongst peoplewith SMI relative to comparison groups. Imputed
estimates for variables with missing data are outlined in the supple-
mentary material (Supplementary Tables 2a–c).
The absolute rate of statin initiation between 2006 and 2015 was
23.7 (95% CI 22.5–25.1) and 28.3 (26.9–39.7) per 1000 person years
for people with bipolar disorder and schizophrenia, relative to 17.1
(16.8–17.4) and 20.7 (20.3–21.0) in the respective comparison groups.
Within age groups temporal patterns of statin prescribing were similar
for individuals with schizophrenia and bipolar disorder: rates of new
statin prescriptions have therefore been combined for both SMI condi-
tions as well as the associated comparison groups. For all years the ini-
tiation rate of statin prescribing was substantially higher in younger
(those aged 30–39 and 40–59 years) individuals with SMI than for indi-
viduals in the comparison cohorts (Fig. 2). Amongst older individuals
(60–74 and 75–99 years), rates of initiation prescribingweremore sim-
ilar for individuals with andwithout SMI. Rates of statin prescribing ini-
tiation to peoplewith SMI aged 40+years increased between 2010 and
2012 to a highs of 33 (40–59 year olds), 57 (60–74 year olds) and 31
(75+ year olds) prescriptions per 1000 person years, with a decline in
initiation thereafter (Fig. 2). Initiation of prescribing rates to comparison
people without SMI showed a consistent decline throughout the study
period, except for those aged 30–39 years where there was less tempo-
ral variation. In more recent years, the gap between initiation of pre-
scribing to people aged 30–74 years with and without SMI has
reduced and now appears similar to 2010 levels.
In the fully adjustedmodel (Model 2) the incident rate ratio (IRR) for
initiation of statin prescribing to the oldest individuals (75–99 years)
with schizophrenia were lower than people without SMI (IRR 0.81
(95% CI 0.66–0.98)), whereas rates of statin prescribing to individuals
with bipolar disorder for the same age group were comparable to peo-
ple without (IRR 0.92 (0.74–1.15)) (Table 3). In contrast, initiation of
statins to people with SMI was higher in individuals aged 30–39 years
(IRR 2.24 (1.64–3.07) for bipolar disorder and 3.26 (2.48–4.29) for
schizophrenia) and for 40–59 year olds (IRR 1.68 (1.53–1.84) for bipolar
disorder and 1.68 (1.53–1.82) for schizophrenia) than those without
SMI. Amongst individuals aged 60–74 years, rates of statin initiation
were similar for people with a diagnosis of schizophrenia (IRR 1.00
(0.91–1.11), but higher for bipolar disorder (IRR 1.15 (1.03–1.28)) com-
pared to people without SMI. There were small (ranging from 0.5% in
people aged 30–39 years to 1.9% in people aged 60–74 years) but statis-
tically signiﬁcant differences in the estimated CVD risk scores of people
with and without SMI who were in the same age band. At ages 30–
74 years people with SMI had relatively higher estimated risk scoresn= 66,060 n= 11,994 n= 59,765
No SMI (%) Bipolar disorder (%) No SMI (%)
20,670 31% 4379 37% 21,883 37%
28,585 43% 5254 44% 26,231 44%
11,429 17% 1670 14% 8277 14%
5376 8% 691 6% 3374 6%
47.5 [37.5–60.5] 44.5 [35.9–56.5] 44.5 [35.9–56.5]
39,365 60% 4727 39% 23,549 39%
13,317 20% 2165 18% 13,849 23%
13,000 20% 2245 19% 12,996 22%
14,565 22% 2655 22% 13,211 22%
13,746 21% 2767 23% 11,544 19%
11,432 17% 2162 18% 8165 14%
rk, BMI; body mass index.
ention of cardiovascular disease amongst people with severe mental
i.org/10.1016/j.schres.2017.05.028
Table 2a
Characteristics of the study population measured during the period January 2007 to December 2007.
Characteristic n= 7503 n= 38,683 n= 6603 n= 33,268
Schizophrenia (%) No SMI (%) p Bipolar disorder (%) No SMI (%) p
Median age at startin years [IQR] 51 [41–63] 52 [41–63] 0.48 48 [40–60] 49 [40–60] 0.52
Sex Males 4298 57% 22,124 57% 0.99 2551 39% 12,906 39% 0.98
Diabetes Yes 331 4% 868 2% b0.001 204 3% 680 2% b0.001
Antihypertensive Yes 1111 15% 6488 17% b0.001 1096 17% 4918 15% b0.001
Smoker 2491 57% 5097 31% b0.001 1812 48% 4466 32% b0.001
Not recorded 3094 41% 22,337 58% 2822 43% 19,117 57%
Mean cholesterol (mmol/L) 5.4 (1.2)a 5.5 (1.1)a 0.001 5.6 (1.2)a 5.6 (1.3)a 0.65
Not recorded 5763 77% 32,088 83% 5063 77% 28,172 85%
Mean HDL-C (mmol/L) 1.3 (0.4)a 1.4 (0.5)a b0.001 1.4 (0.4)a 1.5 (0.4)a b0.001a
Not recorded 6178 82% 33,386 86% 5415 82% 29,155 88%
Mean SBP (mmHg) 130 (17)a 135 (17)a b0.001 130 (16)a 132 (17)a b0.001
Not recorded 3237 43% 22,212 57% 2729 41% 18,798 57%
Mean BMI (kg/m2) 28.1 (6.3)a 27.3 (5.7)a b0.001 27.9 (5.9)a 27.2 (5.8)a b0.001
Not recorded 4342 58% 28,686 74% 3828 58% 24,598 74%
p indicates the p value for a Chi-square or t-test (categorical or continuous variables, respectively) for people with versus without SMI.
a Indicates reporting of a standard deviation in place of a percentage.
4 R. Blackburn et al. / Schizophrenia Research xxx (2017) xxx–xxxthan comparison people, whereas people aged over 75with SMI had es-
timated risk scores that were approximately 1% lower (1.01% (0.50–
1.52) for schizophrenia and 0.82% (0.17–1.46) for bipolar disorder)
than comparison people.
Adjustment for strata of risk score (sensitivity analysis) produced
similar results toModel 2, except amongst 60–74 year olds with bipolar
disorder where the rate of statin initiation no longer differed relative to
people without SMI (IRR 1.08 (0.98–1.19)). Modelling continuous CVD
covariates in linear (as reported) or log linear form (data not shown)
had negligible impact on the association between SMI status and statin
prescribing in either the complete cases or imputed data.
4. Discussion
This study presents the ﬁrst UK data on the initiation of statins pre-
scribed to peoplewith SMI for primary prevention of cardiovascular dis-
ease. The key ﬁndings are that rates of new statin prescribing to people
with SMI are at or above levels in people without SMI, with the excep-
tion of elderly people with schizophrenia who were less frequently ini-
tiated on statins relative to those without SMI. Although the rates of
initiation of statins remain higher amongst people aged 30–74 with
SMI this has decreased in recent years relative to people without SMI,
potentially reﬂecting increased numbers of prevalent statin users
(O'Keeffe et al., 2016) and/or issues with continued engagement of
this group with CVD screening and subsequent interventions. The de-
cline in the initiation of statins prescribed to people without SMI afterTable 2b
Characteristics of the study population measured during the period January 2011 to December
Characteristic n= 6962 n= 38,910
Schizophrenia (%) No SMI (
Median age at start in years [IQR] 50 [41–63] 51 [
Sex Males 4141 59% 22,945 5
Diabetes Yes 448 6% 1247 3
Antihypertensive Yes 1170 17% 7123 1
Smoker 2633 57% 4817 3
Not recorded 2344 34% 24,193 6
Mean cholesterol (mmol/L) 5.3 (1.1)a 5.5 (
Not recorded 4112 59% 31,349 8
Mean HDL-C (mmol/L) 1.3 (0.5)a 1.4 (
Not recorded 4435 64% 32,230 8
Mean SBP (mmHg) 128 (16)a 133 (
Not recorded 2521 36% 23,053 5
Mean BMI (kg/m2) 28.1 (6.3)a 27.5 (
Not recorded 3136 45% 29,251 7
p indicates the p value for a Chi-square or t-test (categorical or continuous variables, respectiv
a Indicates reporting of a standard deviation in place of a percentage.
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at earlier time points (as this study excluded people with prior statin
use) or increased reporting of adverse effects of these drugs (O'Keeffe
et al., 2016).
Ourﬁnding that 30–59 year oldswith SMIweremore frequently ini-
tiated a statin than those without SMI differs markedly to historic stud-
ies that have reported lower levels of use amongst this group. For
example, meta-analysis of 61 comparative studies estimated that peo-
ple with SMI were 40% (OR 0.61 (0.39–0.94)) less likely than people
without mental illness to be prescribed a statin (Mitchell et al., 2012).
However, this estimate includes people with prior CVD diagnoses and
combines data from awide-variety of geographical locations and health
systems (Mitchell et al., 2012) and there have been marked temporal
changes in both the initiation of statins and the pool of people with
on-going use (O'Keeffe et al., 2016), thus direct comparison is difﬁcult.
The relatively higher rate of statin initiation to younger people with
SMI (compared to people without SMI of a similar age) identiﬁed in
this study was not fully explained by differences in CVD risk amongst
this group. However, our study conﬁrms well-documented reports
that people with SMI are more likely to have greater levels of socioeco-
nomic deprivation and to have characteristics – such as a higher preva-
lence of diabetes (Osborn et al., 2008) and smoking than those without
SMI (de Leon and Diaz, 2005) - that are associated with greater risk of
CVD events and may warrant statin prescribing.
Despite twofold or higher rates of statin initiation amongst younger
individuals with SMI, our results suggest that the oldest people with2011.
n= 6761 n= 36,029
%) p Bipolar disorder (%) No SMI (%) p
42–63] 0.01 48 [40–59] 49 [40–60] 0.01
9% 0.85 2554 38% 13,771 38% 0.64
% b0.001 340 5% 1054 3% b0.001
8% 0.003 1349 20% 5887 16% b0.001
3% b0.001 2045 47% 4280 31% b0.001
2% 2412 36% 22,143 61%
1.1)a b0.001 5.5 (1.1)a 5.5 (1.0)a 0.09
1% 4170 62% 29,699 82%
0.4)a b0.001 1.4 (0.5)a 1.5 (0.5)a b0.001
3% 4437 66% 30,453 85%
16)a b0.001 128 (16)a 131 (16)a b0.001
9% 2463 36% 20,885 58%
5.9)a b0.001 28.1 (6.0)a 27.6 (6.1)a b0.001
5% 3174 47% 26,915 75%
ely) for people with versus without SMI.
ention of cardiovascular disease amongst people with severe mental
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Table 2c
Characteristics of the study population measured during the period January 2015 to December 2015.
Characteristic n= 4647 n= 28,522 n= 4943 n= 28,075
Schizophrenia (%) No SMI (%) p Bipolar disorder (%) No SMI (%) p
Median age at start in years [IQR] 51 [41–62] 52 [43–64] b0.001 49 [41–59] 50 [41–60] b0.001
Sex Males 2833 61% 17,343 61% 0.44 1816 37% 10,636 38% 0.45
Diabetes Yes 406 9% 1215 4% b0.001 360 7% 1071 4% b0.001
Antihypertensive Yes 930 20% 5893 21% 0.31 1253 25% 5402 19% b0.001
Smoker 1583 57% 3178 35% b0.001 1371 45% 3053 33% b0.001
Not recorded 1861 40% 19,444 68% 1902 38% 18,845 67%
Mean cholesterol (mmol/L) 5.3 (1.4)a 5.3 (1.1)a b0.001 5.4 (1.1)a 5.4 (1.0)a 0.04
Not recorded 2932 63% 23,152 81% 3092 63% 23,083 82%
Mean HDL-C (mmol/L) 1.3 (0.4)a 1.5 (0.4)a b0.001 1.4 (0.7)a 1.5 (0.5)a b0.001
Not recorded 3030 65% 23,469 82% 3182 64% 23,375 83%
Mean SBP (mmHg) 127 (15)a 133 (16)a b0.001 126 (15)a 130 (16)a b0.001
Not recorded 1807 39% 18,162 64% 1715 35% 17,500 62%
Mean BMI (kg/m2) 28.5 (6.7)a 27.8 (6.2)a b0.001 28.5 (6.6)a 27.8 (6.4)a b0.001
Not recorded 2539 55% 22,450 78% 2627 53% 21,832 78%
p indicates the p value for a Chi-square or t-test (categorical or continuous variables, respectively) for people with versus without SMI.
a Indicates reporting of a standard deviation in place of a percentage.
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these lower rates of prescribing to people with SMI could reﬂect a num-
ber of scenarios including differences in those already prescribed a stat-
in or lower uptake of CVD screening amongst older people with SMI
than older people without SMI, or a lack of clarity regarding prescribing
to individuals aged over 75 years. Other studies investigating provision
of cardiovascular medication for secondary prevention to people with
SMI suggest that greater severity of mental illness and schizophrenia
as associated with lower frequency of prescribing (Woodhead et al.,
2016; Mitchell et al., 2012). In our study there was some evidence that
older people (75+ years) with SMI might have slightly lower CVD
risk than comparison people, potentially reﬂecting a healthy survivor
effect of thosewith less severemental illness. However, the rate of statin
initiation to the oldest people with schizophrenia remained lower than
for comparison people after statistical adjustment for these differences.
Furthermore, it should be noted that the Framingham risk score is not
validated for ages N74 years and thus results for older ages should be
interpreted with caution.
Numerous policy changes and delays between their publication and
ofﬁcial implementation makes establishing the impact of individualFig. 2. The crude rate of new statin prescribing to individuals with and with
Please cite this article as: Blackburn, R., et al., Statin prescribing for prev
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indicates that ﬂuctuations in new statin prescribing to people with
SMI coincide with some policy changes. In particular, the rise in statin
initiation to people with SMI between 2010 and 2012 corresponds
with introduction of an incentive scheme for GPs in England to screen
for cholesterol and CVD risk in people with SMI (Qureshi et al., 2016).
Perhaps surprisingly, our results (Fig. 2) provide no indication that the
decreased threshold of CVD risk for statin prescribing for primary pre-
vention (reducing the risk threshold from 20% ten year risk to 10% in
2014) (National Institute for Health and Clinical Excellence, 2014b;
National Institute for Health and Clinical Excellence, 2008) has been ac-
companied by increased prescribing rates. Future research evaluating of
the impact of primary prevention strategies on CVD events in people
with and without SMI is needed and could help optimise future policy
for prevention.
Our study has some important limitations. In particular, because our
data do not routinely capture CVD risk scores that were estimated by
the GP it was not possible to examine the proportion of people who
were screened, subsequently determined to have high risk (i.e. N10%
after 2014) and who then received statins. Given the excess CVDout SMI by calendar year between January 2006 and December 2015.
ention of cardiovascular disease amongst people with severe mental
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Table 3
Crude rates of statin initiation and adjusted incident rate ratios for statin prescribing in people with (versus without) severe mental illness.
SMI type Age group (yrs) SMI No SMI Adjusted IRR: Model 1 Adjusted IRR: Model 2 Sensitivity analysis
Adjusted IRR: Model 3
Crude rate 95% CI Crude rate 95% CI aIRR 95% CI p value aIRR 95% CI p value aIRR 95% CI p value
Schizophrenia 30–39 11.4 (9.53–13.6) 2.33 (2.07–2.63) 4.77 (3.84–5.93) b0.001 3.26 (2.48–4.29) b0.001 3.54 (2.75–4.54) b0.001
40–59 30.1 (28.1–32.3) 16.54 (16.1–17.0) 1.70 (1.58–1.84) b0.001 1.68 (1.53–1.82) b0.001 1.50 (1.38–1.63) b0.001
60–74 53.0 (49.1–51.4) 50.29 (49.1–57.2) 1.00 (0.92–1.08) 0.94 1.00 (0.91–1.11) 0.93 0.92 (0.84–1.01) 0.08
75–99 31.8 (27.3–36.9) 37.87 (36.5–39.3) 0.69 (0.60–0.81) b0.001 0.81 (0.66–0.98) 0.03 0.76 (0.63–0.92) 0.005
Bipolar disorder 30–39 5.79 (4.58–7.30) 1.97 (1.73–2.25) 2.86 (2.22–3.70) b0.001 2.24 (1.64–3.07) b0.001 2.29 (1.69–3.08) b0.001
40–59 25.4 (23.6–27.4) 13.69 (13.2–14.1) 1.70 (1.57–1.83) b0.001 1.68 (1.53–1.84) b0.001 1.46 (1.34–1.60) b0.001
60–74 57.1 (44.1–46.6) 45.35 (52.6–62.1) 1.22 (1.12–1.33) b0.001 1.15 (1.03–1.28) 0.01 1.08 (0.98–1.19) 0.12
75–99 35.7 (30.1–42.2) 37.86 (36.2–39.6) 0.86 (0.72–1.02) 0.09 0.92 (0.74–1.15) 0.47 0.92 (0.74–1.13) 0.44
Model 1 covariates: age, gender, Townsend score.
Model 2 covariates: age, gender, Townsend score, diabetes, antihypertensive use, smoking status, total cholesterol, HDL-C, BMI, systolic blood pressure.
Model 3 covariates: age, gender, Townsend score, CVD risk score.
6 R. Blackburn et al. / Schizophrenia Research xxx (2017) xxx–xxxmorbidity in this group, it is important to keep emphasising the need for
early CVD screening and intervention in this group and future studies
could focus on this pathway. We were also not able to investigate up-
take of other interventions such as lifestylemodiﬁcations including die-
tary changes or over the counter sales of low-dose simvastatin, although
uptake via this route is likely to be low due to unfavourable costs rela-
tive to prescribed medication. Our study was restricted to the analysis
of data for people registeredwith a general practice.Whilst this popula-
tion is largely representative of the UK, certain groups at high risk of
mental illness (e.g. prisoners and the homeless) are likely to be missed.
Due to substantial missing data it was necessary to use multiple im-
putation prior to statistical adjustment for differences in cardiovascular
characteristics between people with and without SMI. Whilst multiple
imputation is the best available method for estimating values that are
not missing completely at random it is possible that some residual con-
foundingmay remain, which could conceivably bias our estimates in ei-
ther direction. Conventional CVD risk scores such as Framinghamdonot
reliably predict CVD risk in peoplewith SMI andmay underestimate the
risk of CVD events relative to people without SMI (Osborn et al., 2015).
In our study differentially underestimating CVD risk for SMI groups rel-
ative to the comparison groups would tend to mask unmet prescribing
needs amongst the SMI group. However, differences in age and sex (key
predictors of CVD (D'Agostino et al., 2008; Hippisley-Cox et al., 2008))
were controlled for at both the study design and analysis stage and
data on diabetes and antihypertensive medication were fully observed,
thereby improving control for confounding.
We conclude that for primary prevention of CVD younger people
with SMI have comparable or higher rates of statin initiation than peo-
ple without SMI; however, the magnitude of this difference appears to
be in decline in recent years. For older people with schizophrenia
there are lower rates of statin initiation, and this requires further atten-
tion to determine whether opportunities - such as screening - to pre-
vent CVD are being missed.
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